HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMPACT THERAP-B

14.140

+0.0700.50%

Volume:138.20K

Turnover:1.92M

Market Cap:3.99B

PE:-10.92

High:14.210

Open:13.800

Low:13.640

Close:14.070

52wk High:47.980

52wk Low:10.310

Shares:282.46M

HK Float Shares:282.46M

Volume Ratio:0.03

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.295

ROE:--

ROA:-40.35%

PB:4.40

PE(LYR):-10.92

PS:28.87

Loading ...

Overview Company News Filings

IMPACT THERAP-B Surges Over 11% in Early Trading Following Exclusive Licensing Deal for Cancer Drug Senaparib

IMPACT Therapeutics, Inc. Secures EUR423.50 Million Licensing Deal With Pharmanovia for Senaparib Across 66 Countries

Bulletin Express

Impact Therapeutics Signs Exclusive License Deal with Pharmanovia for Senaparib in Europe, Others

Impact Therapeutics - Eligible for up to EUR 423.50 Mln Plus Tiered Royalties in Pharmanovia Deal

THOMSON REUTERS

Impact Therapeutics - Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand

THOMSON REUTERS

Impact Therapeutics Shareholders Approve Articles of Association Amendments

Impact Therapeutics Nominates Preclinical Candidate for GI Cancers

MT Newswires Live

Impact Therapeutics Names Ceacam5 Dual-payload ADC Imp3201 as Preclinical Candidate

IMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress

Impact Therapeutics Says ESMO 2026 Accepts Posters on Senaparib, Imp1734 and Imp1707 Data

IMPACT Therapeutics to Seek Shareholder Nod on New Share Award Scheme and Articles Amendments at 27 July 2026 EGM

Bulletin Express

IMPACT Therapeutics Unveils 10-Year Share Award Scheme, Plans Charter Update; EGM Set for 27 July 2026

Bulletin Express

Impact Therapeutics Proposes 10-year Share Award Scheme Capped at 5% of Issued Shares

IMPACT Therapeutics Schedules 27 July 2026 Extraordinary General Meeting; Share Transfer Books Close 22–27 July 2026

Bulletin Express

Impact Therapeutics Announces Extraordinary General Meeting

Tencent Holdings Boosts Stake in IMPACT THERAP-B with 350,000 Share Purchase at Average Price

Major Shareholder Boosts Stake in IMPACT THERAP-B with Additional 20,000 Shares

IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise

Bulletin Express

IMPACT THERAP-B Issues 6.3 Million H Shares Upon Full Exercise of Over-Allotment Option

IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/07630/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":14.14,"timestamp":1790921737863,"preClose":14.07,"halted":0,"volume":138200,"delay":0,"changeRate":0.004975124378109473,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"Trading","change":0.07,"latestTime":"10-02 14:15:38","open":13.8,"high":14.21,"low":13.64,"amount":1924829,"amplitude":0.040512,"askPrice":14.18,"askSize":800,"bidPrice":14.14,"bidSize":6000,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790928600000},"marketStatusCode":2,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":14.07,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"volumeRatio":0.030827,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.294715,"volumeRatio":0.030827,"shares":282461530,"dividePrice":0,"high":14.21,"amplitude":0.040512,"preClose":14.07,"low":13.64,"week52Low":10.31,"pbRate":"4.40","psRate":"28.87","week52High":47.98,"institutionHeld":0,"latestPrice":14.14,"committee":0.764706,"eps":-1.294715,"divideRate":0,"volume":138200,"delay":0,"ttmEps":-1.052,"open":13.8,"prevYearClose":20.1,"prevWeekClose":13.5,"prevMonthClose":14.07,"prevQuarterClose":14.07,"fiveDayClose":14.23,"twentyDayClose":14.98,"sixtyDayClose":19.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"07630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1782230400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-09-30","current":-13.374525,"percent":0.525773,"low":-34.323153,"twenty":-29.923784,"median":-13.405621,"eighty":-10.552154,"high":-8.821219,"avg":-18.259383,"sd":8.978018,"marketCap":3974233727},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008},{"date":"2026-07-03","current":-16.26247,"twenty":-32.218614,"median":-29.994357,"eighty":-29.297581,"marketCap":5556442415},{"date":"2026-07-10","current":-15.780707,"twenty":-31.493905,"median":-29.916258,"eighty":-25.475578,"marketCap":5385220035},{"date":"2026-07-17","current":-11.297625,"twenty":-31.022068,"median":-29.816044,"eighty":-15.922995,"marketCap":3869073471},{"date":"2026-07-24","current":-9.271485,"twenty":-30.958502,"median":-29.609087,"eighty":-15.602668,"marketCap":3175898995},{"date":"2026-07-31","current":-10.646015,"twenty":-30.630104,"median":-29.369689,"eighty":-13.307417,"marketCap":3653664669},{"date":"2026-08-07","current":-10.047131,"twenty":-30.493855,"median":-29.24895,"eighty":-10.58915,"marketCap":3454825776},{"date":"2026-08-14","current":-10.299125,"twenty":-30.36699,"median":-25.475578,"eighty":-10.316459,"marketCap":3545960269},{"date":"2026-08-21","current":-10.772628,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"marketCap":3717182649},{"date":"2026-08-28","current":-12.490535,"twenty":-30.224959,"median":-15.896725,"eighty":-10.316459,"marketCap":4310937679},{"date":"2026-09-04","current":-14.62831,"twenty":-30.072679,"median":-15.691688,"eighty":-10.353511,"marketCap":4403575252},{"date":"2026-09-11","current":-12.087934,"twenty":-30.026033,"median":-14.57977,"eighty":-10.495083,"marketCap":3643753737},{"date":"2026-09-18","current":-12.193817,"twenty":-29.977617,"median":-13.665771,"eighty":-10.535977,"marketCap":3680473735},{"date":"2026-09-25","current":-12.65778,"twenty":-29.936332,"median":-13.862539,"eighty":-10.54718,"marketCap":3813230655},{"date":"2026-09-30","current":-13.167654,"twenty":-29.923784,"median":-13.405621,"eighty":-10.552154,"marketCap":3974233727}],"updateTime":1790887568126},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140891841","title":"IMPACT THERAP-B Surges Over 11% in Early Trading Following Exclusive Licensing Deal for Cancer Drug Senaparib","url":"https://stock-news.laohu8.com/highlight/detail?id=1140891841","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140891841?lang=en_us&edition=fundamental","pubTime":"2026-07-31 09:54","pubTimestamp":1785462854,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) saw its share price climb more than 11% in early trading, reaching a high of HK$12.79, representing an 11.02% gain, with trading volume reaching HK$996,900.On July 30, the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107391797","title":"IMPACT Therapeutics, Inc. Secures EUR423.50 Million Licensing Deal With Pharmanovia for Senaparib Across 66 Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=1107391797","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107391797?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:24","pubTimestamp":1785407093,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has entered into an exclusive agreement with global specialty pharmaceutical company Pharmanovia to manufacture, develop and commercialise the PARP1/2 inhibitor senaparib in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878714","title":"Impact Therapeutics Signs Exclusive License Deal with Pharmanovia for Senaparib in Europe, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878714","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878714?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:21","pubTimestamp":1785406891,"startTime":"0","endTime":"0","summary":"BRIEF-IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, OthersJuly 30 (Reuters)-IMPACT Therapeutics Inc7630.HK:EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878268","title":"Impact Therapeutics - Eligible for up to EUR 423.50 Mln Plus Tiered Royalties in Pharmanovia Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878268?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:18","pubTimestamp":1785406701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782548","title":"Impact Therapeutics - Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655782548?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:17","pubTimestamp":1785406678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654011467","title":"Impact Therapeutics Shareholders Approve Articles of Association Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=2654011467","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654011467?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:48","pubTimestamp":1785149311,"startTime":"0","endTime":"0","summary":"Impact Therapeutics shareholders approve articles of association amendmentsImpact Therapeutics shareholders adopted amendments to the articles of association at a July 27, 2026 extraordinary general m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL8Rp10R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654092639","title":"Impact Therapeutics Nominates Preclinical Candidate for GI Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2654092639","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654092639?lang=en_us&edition=fundamental","pubTime":"2026-07-27 14:28","pubTimestamp":1785133700,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  nominated IMP3201, a CEACAM5-targeted dual-payload antibody-drug conjugate , as a preclinical candidate.IMP3201 is the first preclinical candidate developed using its proprietary dual-payload ADC platform, according to a Monday Hong Kong bourse filing. It is being developed to treat gastrointestinal cancers, including colorectal, pancreatic, gastric and esophageal squamous cell carcinoma.Shares of the company fell over 6% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK4007","BK4139","ADC","BK4080","BK4231","BK7095","07630","LENZ","ADC.AU","NETL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654606032","title":"Impact Therapeutics Names Ceacam5 Dual-payload ADC Imp3201 as Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2654606032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654606032?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:30","pubTimestamp":1785108648,"startTime":"0","endTime":"0","summary":"Impact Therapeutics names CEACAM5 dual-payload ADC IMP3201 as preclinical candidateImpact Therapeutics nominated IMP3201 as a preclinical candidate, a CEACAM5-targeted dual-payload antibody-drug conju","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260726:nNDL1wq6CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116790823","title":"IMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1116790823","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116790823?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:40","pubTimestamp":1784504433,"startTime":"0","endTime":"0","summary":"The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652198268","title":"Impact Therapeutics Says ESMO 2026 Accepts Posters on Senaparib, Imp1734 and Imp1707 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2652198268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652198268?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:30","pubTimestamp":1784503848,"startTime":"0","endTime":"0","summary":"Impact Therapeutics says ESMO 2026 accepts posters on senaparib, IMP1734 and IMP1707 dataImpact Therapeutics disclosed multiple oncology study abstracts accepted for poster presentation at the 2026 ES","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nNDL1trcy6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131853640","title":"IMPACT Therapeutics to Seek Shareholder Nod on New Share Award Scheme and Articles Amendments at 27 July 2026 EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1131853640","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131853640?lang=en_us&edition=fundamental","pubTime":"2026-07-10 21:46","pubTimestamp":1783691181,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has scheduled its first extraordinary general meeting (EGM) of 2026 for 10:00 a.m. on 27 July 2026 at the company’s Board Room, 27F, New Bund Times Square, 399 West Haiyang...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108414816","title":"IMPACT Therapeutics Unveils 10-Year Share Award Scheme, Plans Charter Update; EGM Set for 27 July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1108414816","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108414816?lang=en_us&edition=fundamental","pubTime":"2026-07-10 21:45","pubTimestamp":1783691159,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) has issued a circular convening an extraordinary general meeting (EGM) for 10:00 a.m. on 27 July 2026 in Shanghai to seek shareholder approval on two...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650380871","title":"Impact Therapeutics Proposes 10-year Share Award Scheme Capped at 5% of Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650380871","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650380871?lang=en_us&edition=fundamental","pubTime":"2026-07-10 21:26","pubTimestamp":1783690001,"startTime":"0","endTime":"0","summary":"Impact Therapeutics proposes 10-year share award scheme capped at 5% of issued sharesImpact Therapeutics proposed a 2026 share award (existing shares) scheme, subject to shareholder approval at an ext","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL27ydXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152854319","title":"IMPACT Therapeutics Schedules 27 July 2026 Extraordinary General Meeting; Share Transfer Books Close 22–27 July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1152854319","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152854319?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:22","pubTimestamp":1783509734,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has announced that its first extraordinary general meeting (EGM) for 2026 will be held on Monday, 27 July 2026. The company’s register of members will be closed from...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649989709","title":"Impact Therapeutics Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2649989709","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649989709?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:13","pubTimestamp":1783509227,"startTime":"0","endTime":"0","summary":"Impact Therapeutics announces extraordinary general meetingImpact Therapeutics will hold its 2026 first extraordinary general meeting on July 27, 2026, in Hong Kong.The company will publish a circular","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDLyLlBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106472584","title":"Tencent Holdings Boosts Stake in IMPACT THERAP-B with 350,000 Share Purchase at Average Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1106472584","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106472584?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:43","pubTimestamp":1783338221,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, Tencent Holdings Limited increased its holding in IMPACT THERAP-B (07630) on June 30. The company acquired 350,000 shares at an average...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IEMG","07630","EWH","BK4504","BK4585","EDZ","BK4581","BK1161","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124994675","title":"Major Shareholder Boosts Stake in IMPACT THERAP-B with Additional 20,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1124994675","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124994675?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:21","pubTimestamp":1782742888,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on June 24th, shareholder Shi Yi increased their holdings in IMPACT THERAP-B (07630) by 20,000 shares. The transaction was executed at...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","EWH","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157701649","title":"IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1157701649","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157701649?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:23","pubTimestamp":1781130203,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) reported that the joint global coordinators fully exercised the over-allotment option on 10 June 2026, resulting in the issuance and allotment of 6.30...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150770934","title":"IMPACT THERAP-B Issues 6.3 Million H Shares Upon Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1150770934","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150770934?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:16","pubTimestamp":1781129774,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (HKEX: 07630) has announced that on June 10, 2026, it issued and allotted 6.2964 million H shares as a result of the full exercise of the over-allotment option.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179114095","title":"IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1179114095","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179114095?lang=en_us&edition=fundamental","pubTime":"2026-06-08 17:03","pubTimestamp":1780909380,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":97,"code":"91000000","status":"200"}]}}